Meeting
2021 ASCO Annual Meeting
Sputum supernatant as a viable alternative for liquid biopsy in advanced non-small cell lung cancer.
Authors
Cheng-Zhi Zhou
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Cheng-Zhi Zhou , Xiaohong Xie , Jianhui Wu , Bingpeng Guo , Yinyin Qin , Xinqing Lin , Ming Liu , Luting Qiu , Xiao Zou , Zhange Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3053)
DOI
10.1200/JCO.2021.39.15_suppl.3053
Abstract #
3053
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).
First Author: Christian Diego Rolfo
Poster
2022 ASCO Annual Meeting
Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx).
First Author: Xiuning Le
Poster
2022 ASCO Annual Meeting
Plasma first: Accelerating lung cancer diagnosis through liquid biopsy.
First Author: Miguel Garcia Pardo
Poster
2021 ASCO Annual Meeting
A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors.
First Author: Andre Marcio Murad